GHK-Cu test results: how often vials pass lab testing
GHK-Cu had the best pass rate of the 14 peptides we track. One in four recent samples still failed. Here are the numbers and where the injectable form stands with FDA.
Of the last 194 GHK-Cu samples with a result in Finnrick's public lab-testing database, 143 passed and 51 failed: 74 percent of GHK-Cu test results were a pass. Another 6 came back incomplete and are left out. Finnrick has published 1,020 GHK-Cu tests from 156 sellers since 22 Apr 2025.
GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma. Unlike most research peptides it has a long track record in skincare and real human topical data behind it. The results here are of GHK-Cu sold as vials by peptide sellers, which is a separate question from a cream on a shelf.
The short version
- 74 percent of recent samples passed. 143 passed and 51 failed, of the last 194 with a result.
- The injectable form is not FDA-approved. FDA plans to take it to its compounding committee before the end of February 2027.
- A pass is a narrow result. It covers identity, purity and fill for the vial that was tested. It does not cover endotoxin, sterility or the next batch.
- We do not name sellers. The numbers describe the market, not any one shop.
GHK-Cu test results in numbers
| Measure | GHK-Cu |
|---|---|
| Published tests | 1,020 |
| Sellers with at least one test | 156 |
| First and latest test | 22 Apr 2025 to 6 Nov 2026 |
| Recent results counted | 194 (6 incomplete left out) |
| Passed | 143 |
| Failed | 51 |
| Pass rate | 74% |
| Rank by pass rate | 1 of 14 on our peptide test results page |
Figures from Finnrick's public GHK-Cu page, checked on 12 November 2026. They will change as new results come in.
What counts as a pass or a fail
These figures use Finnrick's "Purity focus" standard, the one its public pages show. A sample passes when its purity is at least 99.5 percent and the amount in the vial is within 35 percent of the label. A sample that turns out to be a different molecule fails under every standard Finnrick uses. Endotoxin testing is not required under this standard, so a pass says nothing about endotoxin or sterility.
The pass rate counts passes and fails among the most recent results on Finnrick's public page, up to 200, and leaves out tests that came back incomplete. Finnrick says it sources samples from sellers and sends them to third-party labs, with HPLC as the main method. Its methodology page has the detail.
Is GHK-Cu FDA-approved?
No injectable GHK-Cu product is FDA-approved. FDA took injectable GHK-Cu out of Category 2 in April 2026 after its nominator withdrew it, and after one nominator clarified on 5 May 2026 that only the injectable route was withdrawn, the non-injectable routes went back to Category 1 from 14 May 2026. Leaving Category 2 does not make a substance compoundable. Our page on FDA Category 2 peptides covers each step, and FDA says it will consult its compounding committee on injectable GHK-Cu before the end of February 2027.
The best pass rate of the 14, and still one in four failed
GHK-Cu ranked first of the 14 compounds on our peptide test results page. That is the good news, and it is relative. Of the last 194 samples with a result, 51 failed, roughly one in four.
A copper complex adds its own question. The test standard used here checks identity, purity and fill. It does not tell you how much free copper is in a vial, and that would need its own method. Finnrick has published 1,020 GHK-Cu tests from 156 sellers since 22 Apr 2025.
Before you buy GHK-Cu
There is no approved injectable GHK-Cu product for a prescriber to write for, and it is not covered by HHS's October 2026 draft compounding policy. Topical cosmetic products are a separate category.
Before any order, three checks come first: the steps in how to vet a peptide supplier, an independent result for your own lot (how to get peptides tested), and the legal picture in is it legal to buy peptides. Products sold as research use only are not FDA-approved drugs, and a passing test does not make one safe to use.
Peptide AI is building a marketplace with two ways to buy: on a prescription through licensed telehealth, for what can legally be prescribed, or from vetted suppliers with an independent lab report you read before you order. It is not open yet. Early access is here.
Questions people ask
What percentage of GHK-Cu fails lab testing?
In Finnrick's public test database, 51 of the last 194 GHK-Cu samples with a result failed, which is 26 percent, and 143 passed. Tests that came back incomplete are left out.
Is GHK-Cu FDA-approved?
The injectable form is not FDA-approved. FDA plans to take it to its compounding committee before the end of February 2027.
Does a passing lab test mean GHK-Cu is safe?
No. A pass means the sample matched its label on identity, purity and fill under one standard. It does not cover endotoxin, sterility, other vials, or whether GHK-Cu is safe or does anything in people.
Is topical GHK-Cu the same as injectable GHK-Cu?
No. Topical GHK-Cu is used in cosmetics and has human skin data. The injectable research product is a different use with a different regulatory status, and the results on this page are of vials sold by peptide sellers, not of skincare products.
Sources
- Methodology, Finnrick, accessed 12 November 2026
- GHK-Cu product page and public test history, Finnrick, accessed 12 November 2026
